PT - JOURNAL ARTICLE AU - Gary Tse AU - Christina Ip AU - King Sum Luk AU - Mengqi Gong AU - Yan Yee Ting AU - Ishan Lakhani AU - George Bazoukis AU - Guangping Li AU - Konstantinos P Letsas AU - Mei Dong AU - Tong Liu AU - Martin C S Wong TI - Prognostic value of soluble ST2 postaortic valve replacement: a meta-analysis AID - 10.1136/heartasia-2017-010980 DP - 2018 Mar 01 TA - Heart Asia PG - e010980 VI - 10 IP - 1 4099 - http://heartasia.bmj.com/content/10/1/e010980.short 4100 - http://heartasia.bmj.com/content/10/1/e010980.full AB - Objectives Soluble suppression of tumorigenicity 2 (sST2) is a member of the interleukin-1 receptor family and a modulator of hypertrophic and fibrotic responses. Its prognostic value for patients undergoing aortic valve replacement (AVR) has been examined in prospective studies but to date, there has been no systematic evaluation or meta-analysis on this issue.Methods PubMed and Embase were searched until 1 October 2017 for studies that evaluated the relationship between sST2 levels and mortality after AVR.Results A total of 18 and 37 entries were retrieved from both databases, from which four studies were included in the final meta-analysis. In a total of 1154 subjects (50% male, mean age 80±10 years old, mean follow-up 14 months), elevated sST2 levels were significantly associated with a 44% increase in the risk of all-cause mortality (HR 1.44, 95% CI 1.30 to 1.60, p<0.0001; I2: 44%).Conclusions sST2 significantly predicts all-cause mortality in patients who have undergone AVR, but this conclusion is limited by the small number of patients. Larger prospective studies are required to better elucidate its value for risk stratification in this patient population.